ClinicalTrials.gg
RecruitingNCT06082934Updated Oct 13, 2023

Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

A Phase 1/2 interventional study of Olverembatinib plus venetoclax and dexamethasone in Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-13.

Sponsored by Xijing Hospital · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing olverembatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 10 open to participants now, 10 under way, 2 of them phase 3. olverembatinib · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
8th of 11
30 · median 60
Started
2023
with 1 other
Phase 1/2
Only one
of the 11
Registered
4th of 11
by date
Lead sponsor
1 of 11
Xijing Hospital

Among the 11 studies testing olverembatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 8th largest by planned enrollment, is one of 2 that started in 2023, is the only one in phase 1/2, and was the 4th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

10 of the 11 studies testing olverembatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About olverembatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing olverembatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The purpose of this study is to explore the efficacy and safety of the OVD chemotherapy-free regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed Ph+ALL.

Read the detailed description

PRIMARY OBJECTIVES:

To determine the Complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) rates, the measurable residual disease (MRD) rates, the complete molecular remissions (CMR) rates and the progression-free survival (PFS) of the OVD chemotherapy-free regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed Ph+ALL.

SECONDARY OBJECTIVES:

To describe the toxicities of the OVD regimen. To assess the quality of life and overall survival of the OVD chemotherapy-free regimen in patients with newly-diagnosed Ph+ALL.

03

Conditions studied

  • Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of newly-diagnosed Ph+ acute lymphoblastic leukemia
  • Age >= 18
  • Adequate hepatic function
  • Adequate renal function
  • Adequate heart function
  • of more than 3 months
  • Women of and men with partners of child-bearing potential must agree to use 2 methods of or be surgically sterile or abstain from heterosexual activity from the time of signing the for through 120 days after the last dose of study medication.
  • Women of childbearing potential have negative pregnancy test within 72 hours of initiating study drug dosing.
  • Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential even if they have had a successful vasectomy starting with the first dose of study therapy through 120 days after the last dose of study therapy.
  • All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
  • Females of must adhere to the scheduled pregnancy testing as required in the POMALYST REMS program.

Exclusion criteria

Exclusion Criteria:

  • Current or anticipated use of other agents.
  • Female patients who are lactating or have a positive serum pregnancy test during the screening period.
  • Major surgery within 3 weeks prior to first dose
  • Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
  • Known or suspected infection, known HIV seropositivity
  • Active hepatitis infection
  • Has known with a (FEV1) \<50% of predicted normal
  • Known gastrointestinal disease or procedure that could interfere with the oral absorption or tolerance, including difficulty swallowing
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    OVD regimen of Olverembatinib plus venetoclax and dexamethasone

    Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28

    Drug: Olverembatinib plus venetoclax and dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) rates

    Time frame: Three years

  2. Negative measurable residual disease (MRD) rates

    Time frame: Three years

  3. Complete molecular remissions (CMR) rates

    Time frame: Three years

  4. Progression-free survival (PFS)

    Time frame: Three years

07

Study locations

1 of 1 sites recruiting
  • Department of Hematology, Xijing Hospital, Fourth Military Medical University
    Xi'an, Shannxi 710032, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Nov 2026, 36 months later.

Of 81 non-industry phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 119. This study's planned 36 months is below that.

Counting every sponsor, half of 114 studies reached it within 79 months; a quarter within 56 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2023
First posted
Oct 13, 2023
StartEst.
Nov 1, 2023
Primary completionEst.
Nov 1, 2026
CompletionEst.
Nov 1, 2026
Last update
Oct 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06082934
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Nov 1, 2023 (estimated)
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Oct 13, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olverembatinib · Venetoclax · Dexamethasone

Start the discussion